A Novel Anti-CD47 Nanobody Tetramer for Cancer Therapy
CD47 acts as a defense mechanism for tumor cells by sending a “don’t eat me” signal via its bond with SIRPα. With CD47’s overexpression linked to poor cancer outcomes, its pathway has become a target in cancer immunotherapy. Though monoclonal antibodies offer specificity, they have limitations like...
Main Authors: | Nataliya M. Ratnikova, Yulia Kravchenko, Anna Ivanova, Vladislav Zhuchkov, Elena Frolova, Stepan Chumakov |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-01-01
|
Series: | Antibodies |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4468/13/1/2 |
Similar Items
-
Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis
by: Hongcheng Yang, et al.
Published: (2019-08-01) -
Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential
by: Linlin Ma, et al.
Published: (2020-01-01) -
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
by: Wenting Zhang, et al.
Published: (2020-01-01) -
Generation and characterization of antagonistic anti-human CD39 nanobodies
by: Stephan Menzel, et al.
Published: (2024-03-01) -
Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer
by: Akane Sugimura-Nagata, et al.
Published: (2021-03-01)